QWQingzhu Wang

Qingzhu Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qingzhu Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Da Zhou

    Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Feng Guo

    Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou 450001, China

    1 shared publication
  • Guijun Qin

    Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

    1 shared publication
  • Jiahao Song

    Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China

    1 shared publication
  • Lei Ren

    Institute of Integrative Plant Biology, School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu 221116, China

    1 shared publication
  • Lina Wu

    School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, China

    1 shared publication

Latest Publications

  • Open Access

    Understanding Drug Interactions in Antiplatelet Therapy for Atherosclerotic Vascular Disease: A Systematic Review

    by Xiangqian Huang, Jiahao Song, Xiaoming Zhang, Mengqi Wang, Yuchuan Ding, Xunming Ji, Da Zhou, Ran Meng

    Background: Antiplatelet drugs are a cornerstone in managing atherosclerotic vascular disease (ASVD). However, their interactions with other medications present significant challenges to treatment efficacy and safety. Patients with ASVD often require multiple treatment regimens due to complex comorbidities, which increases the risk of drug–drug interactions (DDIs). These interactions can lead to drug resistance, reduced therapeutic outcomes, or adverse effects. A thorough understanding of DDIs is crucial for optimizing patient care. Aims: This review aims to explore the clinical significance. mechanisms, and implications of DDIs in antiplatelet therapy Additionally, it seeks to identify future research directions to advance personalized treatment strategies and improve therapeutic outcomes. Materials and Methods: A systematic literature review was conducted using key databases, focusing on clinical studies, mechanistic research, and guidelines related to antiplatelet therapy and DDIs. Findings were analyzed to identify common interaction patterns, associated risks, and management strategies. Results: The review identifies common DDIs involving antiplatelet drugs, particularly with anticoagulants, nonsteroidal anti‐inflammatory drugs, and proton pump inhibitors. These interactions primarily occur through pharmacokinetic mechanisms, such as alterations in drug metabolism via cytochrome P450 enzymes, and pharmacodynamic mechanisms, including synergistic or antagonistic effects on platelet inhibition. Clinically, DDIs can increase bleeding risk, reduce antiplatelet efficacy, and contribute to adverse cardiovascular outcomes. Strategies to mitigate these risks include individualized drug selection, dose adjustments, genetic testing, and therapeutic drug monitoring. Discussion: Effective management of DDIs in antiplatelet therapy is essential to improve clinical outcomes. A patient‐specific approach, considering comorbidities, genetic predispositions, and concurrent medications, is crucial. The review categorizes DDIs based on clinical settings and underscores the need for further research on predictive biomarkers, pharmacogenomics, and advanced monitoring techniques. Conclusion: DDIs significantly impact the effectiveness and safety of antiplatelet therapy, necessitating a comprehensive understanding of their mechanisms and clinical implications. Future research should focus on developing personalized treatment approaches, integrating genetic testing, and optimizing pharmacological monitoring to minimize risks and improve therapeutic outcomes. This review provides a foundation for advancing clinical practice and enhancing the management of patients with ASVD.


  • Open Access

    A novel stroke rehabilitation strategy and underlying stress granule regulations through inhibition of NLRP3 inflammasome activation

    by Qingzhu Wang, Wesley Kohls, Melissa Wills, Fengwu Li, Qi Pang, Xiaokun Geng, Yuchuan Ding

    Objective: Dynamic changes in ischemic pathology after stroke suggested a “critical window” of enhanced neuroplasticity immediately after stroke onset. Although physical exercise has long been considered a promising strategy of stroke rehabilitation, very early physical exercise may exacerbate brain injury. Since remote ischemic conditioning (RIC) promotes neuroprotection and neuroplasticity, the present study combined RIC with sequential exercise to establish a new rehabilitation strategy for a better rehabilitative outcome.Methods: A total of 120 adult male Sprague‐Dawley rats were used and divided into five groups: (1) sham, (2) stroke, (3) stroke with exercise, (4) stroke with RIC, and (5) stroke with RIC followed by exercise. Brain damage was evaluated by infarct volume, neurological deficit, cell death, and lactate dehydrogenase (LDH) activity. Long‐term functional outcomes were determined by grid walk tests, rotarod tests, beam balance tests, forelimb placing tests, and the Morris water maze. Neuroplasticity was evaluated through measurements of both mRNA and protein levels of synaptogenesis (synaptophysin [SYN], post‐synaptic density protein‐95 [PSD‐95], and brain‐derived neurotrophic factor [BDNF]) and angiogenesis (vascular endothelial growth factor [VEGF], angiopoietin‐1 [Ang‐1], and angiopoietin‐2 [Ang‐2]). Inflammasome activation was measured by concentrations of interleukin‐18 (IL‐18) and IL‐1β detected by enzyme‐linked immunosorbent assay (ELISA) kits, mRNA expressions of NLR pyrin domain containing 3 (NLRP3), apoptosis‐associated speck‐like protein containing a C‐terminal caspase recruitment domain (ASC), IL‐18 and IL‐1β, and protein quantities of NLRP3, ASC, cleaved‐caspase‐1, gasdermin D‐N (GSDMD‐N), and IL‐18 and IL‐1β. Stress granules (SGs), including GTPase‐activating protein‐binding protein 1 (G3BP1), T cell‐restricted intracellular antigen‐1 (TIA1), and DEAD‐box RNA helicase 3X (DDX3X) were evaluated at mRNA and protein levels. The interactions between DDX3X with NLRP3 or G3BP1 were determined by immunofluorescence and co‐immunoprecipitation.Results: Early RIC decreased infarct volumes, neurological deficits, cell death, and LDH activity at post‐stroke Day 3 (p < 0.05). All treatment groups showed significant improvement in functional outcomes, including sensory, motor, and cognitive functions. RIC and exercise, as compared to RIC or physical exercise alone, had improved functional outcomes after stroke (p < 0.05), as well as synaptogenesis and angiogenesis (p < 0.05). RIC significantly reduced mRNA and protein expressions of NLRP3 (p < 0.05). SGs formation peaked at 0 h after ischemia, then progressively decreased until 24 h postreperfusion, which was reversed by RIC (p < 0.05). The assembly of SGs consumed DDX3X and then inhibited NLRP3 inflammasome activation.Conclusions: RIC followed by exercise induced a better rehabilitation in ischemic rats, while early RIC alleviated ischemia‐reperfusion injury via stress‐granule‐mediated inhibition of NLRP3 inflammasome.


  • Open Access

    Overexpression of the FoxO1 Ameliorates Mesangial Cell Dysfunction in Male Diabetic Rats

    by Guijun Qin, Yingni Zhou, Feng Guo, Lei Ren, Lina Wu, Yuanyuan Zhang, Xiaojun Ma, Qingzhu Wang

    The dysfunction of mesangial cells (MCs) in high-glucose (HG) conditions plays pivotal role in inducing glomerular sclerosis by causing the imbalance between generation and degradation of extracellular matrix (ECM) proteins, which ultimately leads to diabetic nephropathy. This study was designed to determine the function of forkhead box protein O1 (FoxO1), an important transcription factors in regulating cell metabolism and oxidative stress, in MCs in HG conditions. Up-regulation of fibronectin, collagen type IV, and plasminogen activator inhibitor (PAI-1) was observed under HG conditions in vivo and in vitro, accompanied with elevation of protein kinase B (Akt) phosphorylation and reduction of FoxO1 bioactivity. After overexpression of constitutively active (CA) FoxO1 in vivo and in vitro by using lentivirus vector, in vivo and in vitro, FoxO1 expression and activity was increased, in accordance with up-regulation of antioxidative genes (catalase and superoxide dismutase, leading to alleviated oxidative stress as well as attenuated Akt activity, whereas overexpression of wild type-FoxO1 only expressed partial effect. Moreover, CA-FoxO1 decreased the expression of fibronectin, collagen type IV, and PAI-1, causing amelioration of renal pathological changes and decrease of ECM protein deposition in glomerulus. Overexpression of CA-FoxO1 in renal cortex also decreased activin type-I receptor-like kinase-5 levels and increased signaling mothers against decapentaplegic (Smad) 7 levels, and simultaneously inhibited Smad3 phosphorylation. Results from in vitro study indicated that increased combination of FoxO1 and Smad3 may interfere with the function of Smad3, including Smad3 phosphorylation and translocation, interaction with cAMP response element binding protein (CREB)-binding protein, and binding with PAI-1 promoter. Together, our findings shed light on the novel function of FoxO1 in inhibiting ECM deposition, which is beneficial to ameliorate MC dysfunction.